Repligen corporation

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs, repligen corporation. BeforeRepligen maintained dual capabilities in developing pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug repligen corporation bioprocessing business. Repligen employs a direct sales model to users of its products in the United States, with some sales through intermediaries in "certain foreign markets". As lawn mowing oran park consequence of current operations, about one-third each of revenue and cost and expenses are denominated in Swedish krona currency, the remaining two-thirds denominated in United States repligen corporation ; this presents a risk to the business based on unpredictable fluctuations in currency exchange rates, repligen corporation.

Overcome common challenges. Push the boundaries of what's possible. Maximize productivity at every step. Simplify complex workflows. Accelerate new modalities. Leverage technology breakthroughs and expert engineering.

Repligen corporation

Powered by. Repligen Corp Repligen is a life science company that develops and commercializes bioprocessing technologies for the manufacturing of biological drugs. Its products include upstream and downstream filtration, chromatography products, fluid management, cell culture supplements, ligands, and operating room disposables. The company also provides solutions to overcome the development and production of modalities into a new class of drugs. Its services comprise hands-on-process and implementation consultation services. Repligen is headquartered in Waltham, Massachusetts, the US. History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events. Have you found what you were looking for? Contact the team or request a demo to find out how our data can drive your business forward. Visit Corporate Site. Sign in. Book a demo. Industries We Cover Your curated industry news round-up. Subscribe now.

Maximize productivity at every step. Repligen acquired Metenova, a leading Swedish innovator in magnetic mixing technology for biopharmaceutical production, repligen corporation. Leverage technology breakthroughs and expert engineering.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.

With its stock down 4. Particularly, we will be paying attention to Repligen's ROE today. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder's equity. Check out our latest analysis for Repligen. The 'return' is the amount earned after tax over the last twelve months. Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. When you first look at it, Repligen's ROE doesn't look that attractive.

Repligen corporation

In his most recent role at Cytiva, he served as Bioprocess President from to , overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Loeillot joins Repligen from his most recent role as Chief Executive Officer CEO of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets. At Repligen, Mr. Tony J.

Eurocalas hotel majorca reviews

Parts of this article those related to Entire article need to be updated. Sign in to view your mail. Book consultation. No of Employees 2, Book a demo. Gain competitive edge and increase your chances of success. Leader in Upstream Process Intensification Watch the webinars on history, potential, applications. Toggle limited content width. Empowering a new generation of biologics Repligen provides technology breakthroughs and scalable hardware, software and consumables workflow solutions for the development and manufacture of plasmid DNA, viral vectors, mRNA and new modalities such as whole cells, cultivated meat. Currency in USD. Simplify and intensify.

Tony J. Strategically, our three acquisitions of Polymem, Avitide and BioFlex position us well to continue to drive above market growth in Our financial guidance for the fiscal year is based on expectations for our existing business and includes the financial impact of our acquisitions of BioFlex Solutions which closed on December 16, , Avitide Inc.

News Read More. Click on the image highlights to see key elements of chromatography redesigned. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Book a demo. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk. Repligen acquires FlexBiosys Inc. Expanding Process Analytics: Daylight Solutions. Traded as. Repligen Corp Repligen is a life science company that develops and commercializes bioprocessing technologies for the manufacturing of biological drugs. Alexander Rich was a co-founder of Repligen and served as Chairman Emeritus [14] of Repligen's board of directors. Director; Chief Executive Officer. Be the leader. Save hours of research time and resources with our up-to-date Repligen Corp Strategy Report Understand Repligen Corp position in the market, performance and strategic initiatives.